Q1 FY27 results analysis · August 10, 2026

Gland Pharma Q1 FY27 Results Analysis: PAT Jumps 47%, EBITDA Margin Expands 300 bps

+47.1%PAT year on year, Rs. 316.96 Cr
Cofacto ResearchPublished August 10, 20262 min readPositive read
Quick summary

Gland Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,800.27 Cr (+19.57% YoY) and PAT growth of +47.09% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 10, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,800.27 Cr (+19.57% YoY)
PAT (Q1)Rs. 316.96 Cr (+47.09% YoY)
EBITDA margin27.40% (+300 bps YoY)
EPS (Q1)Rs. 19.23 (+47.02% YoY)
Market capRs. 43,746.69 Cr
CMPRs. 2,651.85

Quarter Snapshot

Gland Pharma delivered a record Q1 with 19.6% YoY revenue growth and 47% PAT growth, driven by strong US market performance and CDMO expansion. EBITDA margin expanded 300 bps YoY. Post-quarter, the Sugammadex launch provides a near-term catalyst. However, subsidiary losses and raw material cost headwinds in coming quarters temper the outlook.

Key Investment Insights

Key Positives

  • Revenue grew 19.57% YoY to Rs.1,800.27 Cr, a record Q1
  • PAT grew 47.09% YoY to Rs.316.96 Cr, outpacing revenue growth
  • EBITDA margin expanded 300 bps YoY to 27.4%
  • CDMO segment grew 20.29% YoY, reaching 49.5% share of revenue
  • US market revenue grew 31.80% YoY, driven by volume and new launches
  • Post-quarter, Sugammadex received USFDA approval with Day-1 launch
  • Net cash position of Rs.3,116 Cr provides balance sheet strength

Risk Factors

  • Subsidiary drag of Rs.47.43 Cr on consolidated PAT, indicating Cenexi still loss-making
  • Raw material cost headwind expected in Q2-Q3 as inventory buffer depletes
  • Canada, Australia & New Zealand market declined 27.74% YoY
  • EBITDA margin compressed 200 bps QoQ from Q4 peak of 29.4%

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.